Germany Market Trends Germany is one of the most developed markets for GLP-1 analogues in Europe, given the high rate of therapy uptake and effective healthcare reimbursement systems
According to studies, Mounjaro may be about 40% more potent than GLP-1 medications like Ozempic or Wegovy for some patients
Canadians ordering research peptides for personal use from international sources generally face minimal legal risk, though quality verification becomes the individuals responsibility
Significant weight reduction may affect oestrogen levels, menstrual regularity, and ovarian function, particularly in women with polycystic ovary syndrome (PCOS) or other underlying reproductive conditions
Patients who communicate openly about side effects, appetite changes, and lifestyle factors give their clinicians the information needed to adjust the dose safely